ReviewFrontiers in microbiology2014
Engineered bacteriophage lysins as novel anti-infectives.
Review in Frontiers in microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed.
- Construction and Characterization of the Novel Engineered Endolysin ALC005: A New Alternative Antimicrobial AgainstMicroorganisms · 2026Article
- Prokaryotic Expression and Preliminary Application of Lys40, an Endolysin from Broad-Host-Range Salmonella enterica Phage SP_4.Current microbiology · 2026Article
- Bacteriophage lysins: a promising strategy for combating foodborne pathogens in food safety.Frontiers in microbiology · 2026Review
- Avian PathogenicVeterinary sciences · 2025Review
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Article
- Biological characterization and antibacterial effects of a novel virulentFrontiers in microbiology · 2025Article
- Agents Targeting the Bacterial Cell Wall as Tools to Combat Gram-Positive Pathogens.Molecules (Basel, Switzerland) · 2024Review
- Review
- You get what you test for: The killing effect of phage lysins is highly dependent on buffer tonicity and ionic strength.Microbial biotechnology · 2024Article
- Engineering strategies and challenges of endolysin as an antibacterial agent against Gram-negative bacteria.Microbial biotechnology · 2024Review
- An Exploratory Review of the Potential of Lytic Proteins and Bacteriophages for the Treatment of Tuberculosis.Microorganisms · 2024Review
- A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.Frontiers in microbiology · 2024Article
- LYZ2-SH3b as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus.BMC microbiology · 2023Article
- New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular Processes.Antibiotics (Basel, Switzerland) · 2023Review
- Treating bacterial infections with bacteriophages in the 21st century.Southern African journal of infectious diseases · 2022Article
- Isolation ofFrontiers in microbiology · 2022Article
- Bacteriophages and related endolysins for reduction of microorganisms in the human body - a systematic review.GMS hygiene and infection control · 2022Review
- An Engineered Multimodular Enzybiotic against Methicillin-ResistantLife (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophage lysins, the highly evolved specific peptidoglycan hydrolases, have long been demonstrated to be effective enzybiotics in various infectious models. The modular structure of lysins makes it possible to design bioengineered lysins that have desired properties, such as higher activity, or broader killing spectrum. Moreover, lysins can even be engineered to kill Gram-negative bacterial pathogens from without, a property that is not present in natural lysins. In this era of ever increasing multidrug resistant pathogens, engineered lysins represent a new class of enzybiotics that are powerful and readily available to fight antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.